PL4084791T3 - Specyficzne tryptaminy do zastosowania w leczeniu zaburzeń nastroju - Google Patents
Specyficzne tryptaminy do zastosowania w leczeniu zaburzeń nastrojuInfo
- Publication number
- PL4084791T3 PL4084791T3 PL21711684.7T PL21711684T PL4084791T3 PL 4084791 T3 PL4084791 T3 PL 4084791T3 PL 21711684 T PL21711684 T PL 21711684T PL 4084791 T3 PL4084791 T3 PL 4084791T3
- Authority
- PL
- Poland
- Prior art keywords
- tryptamines
- treatment
- specific
- mood disorders
- mood
- Prior art date
Links
- 208000019022 Mood disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062978075P | 2020-02-18 | 2020-02-18 | |
| PCT/US2021/018534 WO2021168082A1 (en) | 2020-02-18 | 2021-02-18 | Specific tryptamines for use in the treatment of mood disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4084791T3 true PL4084791T3 (pl) | 2025-04-22 |
Family
ID=74871827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL21711684.7T PL4084791T3 (pl) | 2020-02-18 | 2021-02-18 | Specyficzne tryptaminy do zastosowania w leczeniu zaburzeń nastroju |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US20220241243A1 (pl) |
| EP (2) | EP4084791B1 (pl) |
| JP (3) | JP7242969B2 (pl) |
| KR (2) | KR102567903B1 (pl) |
| CN (2) | CN117503759A (pl) |
| AU (2) | AU2021224899B2 (pl) |
| BR (1) | BR112022016382A2 (pl) |
| CA (1) | CA3172046A1 (pl) |
| DK (1) | DK4084791T3 (pl) |
| ES (1) | ES3014741T3 (pl) |
| FI (1) | FI4084791T3 (pl) |
| HR (1) | HRP20250148T1 (pl) |
| HU (1) | HUE070631T2 (pl) |
| IL (2) | IL301235A (pl) |
| LT (1) | LT4084791T (pl) |
| MX (2) | MX2022010082A (pl) |
| PL (1) | PL4084791T3 (pl) |
| PT (1) | PT4084791T (pl) |
| RS (1) | RS66496B1 (pl) |
| SI (1) | SI4084791T1 (pl) |
| SM (1) | SMT202500143T1 (pl) |
| WO (1) | WO2021168082A1 (pl) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3934633A4 (en) * | 2019-03-07 | 2023-03-29 | Arbormentis LLC | COMPOSITIONS AND METHODS OF USE WITH SUBSTANCES WITH NEURAL PLASTIC EFFECTS ADMINISTRATED IN NON-PSYCHEDELIC/PSYCHOTOMIMETIC DOSES AND FORMULATIONS |
| PL4084791T3 (pl) * | 2020-02-18 | 2025-04-22 | Gilgamesh Pharmaceuticals, Inc. | Specyficzne tryptaminy do zastosowania w leczeniu zaburzeń nastroju |
| EP4146198A4 (en) | 2020-05-08 | 2024-05-15 | Psilera Inc. | Novel compositions of matter and pharmaceutical compositions |
| CN115667217A (zh) | 2020-05-19 | 2023-01-31 | 赛本爱尔兰有限公司 | 氘化的色胺衍生物和使用方法 |
| EP4208445A4 (en) | 2020-09-01 | 2024-10-02 | Enveric Biosciences Canada Inc. | Halogenated psilocybin derivatives and methods of using |
| JP2024523822A (ja) * | 2021-06-02 | 2024-07-02 | セント ジョセフズ ユニバーシティー | フッ素化トリプタミン化合物、その類似体、及びそれを使用する方法 |
| EP4396162A4 (en) * | 2021-09-03 | 2025-11-12 | Alexander Shulgin Res Institute Inc | ASYMMETRIC ALLYL TRYPTAMINES |
| EP4159201A1 (en) | 2021-09-30 | 2023-04-05 | Biomind Labs Inc | Encapsulated microparticles and nanoparticles of dimethyltriptamines |
| EP4423062A4 (en) * | 2021-10-29 | 2025-08-27 | Psilera Inc | MODIFIED INDOLE COMPOUNDS |
| WO2023108174A1 (en) * | 2021-12-10 | 2023-06-15 | Terran Biosciences, Inc. | Analogs of 6-methoxy- n, n-dimethyltryptamine |
| EP4452937A4 (en) * | 2021-12-24 | 2025-12-03 | Psylo Pty Ltd | CONNECTIONS |
| WO2023147424A1 (en) * | 2022-01-27 | 2023-08-03 | Terran Biosciences, Inc. | Salts and solid forms of n-ethyl-2-(5-fluoro-1h-indol-3-yl)- n-methylethan-1-amine |
| US12060328B2 (en) | 2022-03-04 | 2024-08-13 | Reset Pharmaceuticals, Inc. | Co-crystals or salts of psilocybin and methods of treatment therewith |
| CN119255799A (zh) * | 2022-03-27 | 2025-01-03 | Gh研究爱尔兰有限公司 | 用于治疗双相情感障碍的5-meo-dtm |
| KR20250053871A (ko) * | 2022-08-31 | 2025-04-22 | 사이빈 아이알엘 리미티드 | 트립타민 화합물, 조성물, 및 사용 방법 |
| WO2024108195A1 (en) * | 2022-11-17 | 2024-05-23 | Remedi, Inc. | Combinations of monoamine oxidase inhibitors and serotonin receptor agonists and their therapeutic use |
| US12396981B2 (en) | 2023-03-09 | 2025-08-26 | William Shulman | Methods of using DMT |
| AU2024309903A1 (en) | 2023-06-28 | 2026-01-08 | Psylo Pty Ltd | Compounds |
| WO2025000051A1 (en) | 2023-06-28 | 2025-01-02 | Psylo Pty Ltd | Pyrrolopyridine compounds for the treatment of mental illnesses |
| US12129234B1 (en) * | 2023-08-03 | 2024-10-29 | Gilgamesh Pharmaceuticals, Inc. | Crystalline salts of N-ethyl-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine |
| US12180158B1 (en) * | 2023-08-03 | 2024-12-31 | Gilgamesh Pharmaceuticals, Inc. | Crystalline fumarate salts of n-ethyl-2-(5-fluoro-1H-indol-3-yl)-n-methylethan-1-amine |
| WO2025052388A1 (en) * | 2023-09-07 | 2025-03-13 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Psychedelic compounds, methods of their preparation and uses thereof |
| WO2025111597A1 (en) * | 2023-11-22 | 2025-05-30 | Gilgamesh Pharmaceuticals, Inc. | A treatment for patients with mood disorders using n-ethyl-2-(5-fluoro-1h-indol-3-yl)- n-methylethan-1-amine or a pharmaceutically acceptable salt thereof |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB853775A (en) | 1957-09-19 | 1960-11-09 | Parke Davis & Co | Pharmaceutical compositions and methods for producing phenylcyclohexane compounds |
| DE1668550A1 (de) | 1967-09-19 | 1971-07-22 | Parke Davis & Co | 2-Alkoxyalkylamino-2-phenylcyclohexanonverbindungen und ihre Saeure-Additionssalze und Verfahren zu ihrer Herstellung |
| CA1105938A (en) | 1976-06-03 | 1981-07-28 | Daniel Lednicer | 4-amino-4-arylcyclohexanone ketals |
| US4065573A (en) | 1976-06-03 | 1977-12-27 | The Upjohn Company | 4-Amino-4-phenylcyclohexanone ketal compositions and process of use |
| CA1100516A (en) | 1976-06-03 | 1981-05-05 | Daniel Lednicer | 4-amino-4-arylcyclohexanones and their ketals |
| ITRM20010356A1 (it) | 2001-06-21 | 2002-12-23 | Sigma Tau Ind Farmaceuti | "5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina. |
| DE60309324T2 (de) | 2002-06-21 | 2007-05-10 | Suven Life Sciences Ltd. | Tetracyclische arylcarbonyl indole mit serotoninrezeptoraffinität als arzneimittel, verfahren zu ihrer herstellung und pharmazeutische zubereitungen |
| EP1523486B1 (en) | 2002-06-21 | 2007-11-07 | Suven Life Sciences Limited | Tetracyclic arylsulfonyl indoles having serotonin receptor affinity |
| US7297711B2 (en) | 2002-06-21 | 2007-11-20 | Suven Life Sciences Limited | Arylalkyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them |
| DE10252667A1 (de) | 2002-11-11 | 2004-05-27 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| DE10252666A1 (de) | 2002-11-11 | 2004-08-05 | Grünenthal GmbH | N-Piperidyl-cyclohexan-Derivate |
| DE10360793A1 (de) | 2003-12-23 | 2005-07-28 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| JP2009504597A (ja) | 2005-08-10 | 2009-02-05 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | アシルトリプトファノール |
| EP1956016A1 (en) | 2006-12-15 | 2008-08-13 | Bayer Schering Pharma Aktiengesellschaft | Bicyclic acyltryptophanols |
| WO2008071455A1 (en) | 2006-12-15 | 2008-06-19 | Bayer Schering Pharma Aktiengesellschaft | Bicyclic acyltryptophanols |
| CA2719739A1 (en) | 2008-03-27 | 2009-10-01 | Sven Frormann | Hydroxymethylcyclohexylamines |
| KR20110110297A (ko) | 2009-01-09 | 2011-10-06 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 불소 함유 화합물 및 이의 사용방법 |
| AU2010251930A1 (en) * | 2009-05-27 | 2011-11-24 | Universite Libre De Bruxelles | 3-alkyl-5-fluoroindole derivatives as myeloperoxidase inhibitors |
| TWI582092B (zh) | 2010-07-28 | 2017-05-11 | 歌林達股份有限公司 | 順式－四氫－螺旋（環己烷－１,１’－吡啶［３,４－b］吲哚）－４－胺－衍生物 |
| CN104276993B (zh) | 2013-07-12 | 2019-03-15 | 广东东阳光药业有限公司 | 吲哚衍生物及其在药物上的应用 |
| US20180021326A1 (en) * | 2016-07-23 | 2018-01-25 | Paul Edward Stamets | Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin |
| WO2018064465A1 (en) * | 2016-09-29 | 2018-04-05 | The Regents Of The University Of California | Compounds for increasing neural plasticity |
| US10933073B2 (en) * | 2017-02-09 | 2021-03-02 | Caamtech Llc | Compositions and methods comprising a psilocybin derivative |
| GB201808150D0 (en) | 2018-05-18 | 2018-07-11 | Small Pharma Ltd | Therapeutic compounds |
| GB201716942D0 (en) | 2017-10-16 | 2017-11-29 | Small Pharma Ltd | Therapeutic compounds |
| EP3713568A1 (en) * | 2017-10-26 | 2020-09-30 | Consejo Superior de Investigaciones Cientificas (CSIC) | Combination product for the treatment of neurological and/or psychiatric disorders |
| EP3505509A1 (en) | 2017-12-29 | 2019-07-03 | Université de Liège | Methods for the preparation of arylcycloalkylamine derivatives |
| CN111936127A (zh) | 2018-02-15 | 2020-11-13 | 国立大学法人千叶大学 | 炎症性疾病或骨病的预防或治疗剂及医药组合物 |
| CN110343050B (zh) | 2018-04-04 | 2021-09-24 | 上海键合医药科技有限公司 | 芳香类化合物及其制备方法和用途 |
| KR102104953B1 (ko) | 2018-04-17 | 2020-04-27 | 삼육대학교 산학협력단 | 신규 케타민 유도체 및 이의 우울증의 예방 또는 치료 용도 |
| TW202026281A (zh) | 2018-12-12 | 2020-07-16 | 西班牙商艾斯提夫製藥股份有限公司 | 用於治療疼痛和疼痛相關病症之新吡咯啶–2– 甲酸衍生物 |
| EP3934633A4 (en) | 2019-03-07 | 2023-03-29 | Arbormentis LLC | COMPOSITIONS AND METHODS OF USE WITH SUBSTANCES WITH NEURAL PLASTIC EFFECTS ADMINISTRATED IN NON-PSYCHEDELIC/PSYCHOTOMIMETIC DOSES AND FORMULATIONS |
| CN115190815B (zh) | 2019-12-26 | 2024-06-18 | 吉尔伽美什制药公司 | 芳基环己基胺衍生物及其在精神障碍的治疗中的用途 |
| PL4084791T3 (pl) * | 2020-02-18 | 2025-04-22 | Gilgamesh Pharmaceuticals, Inc. | Specyficzne tryptaminy do zastosowania w leczeniu zaburzeń nastroju |
| EP4208445A4 (en) * | 2020-09-01 | 2024-10-02 | Enveric Biosciences Canada Inc. | Halogenated psilocybin derivatives and methods of using |
| CN112174851A (zh) | 2020-11-09 | 2021-01-05 | 广州万孚生物技术股份有限公司 | 一种氟胺酮半抗原、氟胺酮抗原及其制备方法和应用 |
| CN113234036B (zh) | 2021-05-12 | 2023-07-14 | 斯莱普泰(上海)生物医药科技有限公司 | Nmda受体拮抗剂及其用途 |
-
2021
- 2021-02-18 PL PL21711684.7T patent/PL4084791T3/pl unknown
- 2021-02-18 CA CA3172046A patent/CA3172046A1/en active Pending
- 2021-02-18 HR HRP20250148TT patent/HRP20250148T1/hr unknown
- 2021-02-18 EP EP21711684.7A patent/EP4084791B1/en active Active
- 2021-02-18 MX MX2022010082A patent/MX2022010082A/es unknown
- 2021-02-18 EP EP24219503.0A patent/EP4501407A3/en active Pending
- 2021-02-18 KR KR1020227028602A patent/KR102567903B1/ko active Active
- 2021-02-18 ES ES21711684T patent/ES3014741T3/es active Active
- 2021-02-18 FI FIEP21711684.7T patent/FI4084791T3/fi active
- 2021-02-18 AU AU2021224899A patent/AU2021224899B2/en active Active
- 2021-02-18 SM SM20250143T patent/SMT202500143T1/it unknown
- 2021-02-18 RS RS20250141A patent/RS66496B1/sr unknown
- 2021-02-18 SI SI202130280T patent/SI4084791T1/sl unknown
- 2021-02-18 JP JP2022549507A patent/JP7242969B2/ja active Active
- 2021-02-18 PT PT217116847T patent/PT4084791T/pt unknown
- 2021-02-18 KR KR1020237027449A patent/KR20230124103A/ko active Pending
- 2021-02-18 DK DK21711684.7T patent/DK4084791T3/da active
- 2021-02-18 HU HUE21711684A patent/HUE070631T2/hu unknown
- 2021-02-18 IL IL301235A patent/IL301235A/en unknown
- 2021-02-18 CN CN202311299060.3A patent/CN117503759A/zh active Pending
- 2021-02-18 BR BR112022016382A patent/BR112022016382A2/pt unknown
- 2021-02-18 CN CN202180015399.9A patent/CN115135320B/zh active Active
- 2021-02-18 WO PCT/US2021/018534 patent/WO2021168082A1/en not_active Ceased
- 2021-02-18 LT LTEPPCT/US2021/018534T patent/LT4084791T/lt unknown
- 2021-08-17 US US17/404,923 patent/US20220241243A1/en not_active Abandoned
- 2021-10-25 US US17/510,080 patent/US11440879B2/en active Active
-
2022
- 2022-08-10 IL IL295536A patent/IL295536B2/en unknown
- 2022-08-16 MX MX2024006123A patent/MX2024006123A/es unknown
-
2023
- 2023-03-07 JP JP2023034728A patent/JP7640600B2/ja active Active
-
2024
- 2024-05-31 US US18/680,473 patent/US20240317683A1/en not_active Abandoned
- 2024-06-28 US US18/758,102 patent/US20240351983A1/en active Pending
-
2025
- 2025-02-20 JP JP2025026050A patent/JP2025071254A/ja active Pending
- 2025-02-20 AU AU2025201184A patent/AU2025201184A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL295536A (en) | Specific tryptamines for use in the treatment of mood disorders | |
| MX2025004367A (es) | Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos | |
| PH12021552856A1 (en) | Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof | |
| IL311485B1 (en) | JAK1 pathway inhibitors for the treatment of cytokine-related disorders | |
| IL271072A (en) | Devices and methods for the treatment of body surface disorders | |
| IL287280A (en) | Compounds and methods for the treatment of ocular disorders | |
| SG11202104053TA (en) | Compositions and methods for the treatment of estrogen-dependent disorders | |
| SG11202103191QA (en) | Benzimidazole derivative for use in the treatment of inflammatory disorders | |
| IL287264A (en) | Compounds and methods for the treatment of ocular disorders | |
| IL289371A (en) | Methylthioninium for use in the treatment of synaptopathies | |
| IL284175A (en) | Dosing regimens in the use of LY3154207 in the treatment of diseases of the dopaminergic central nervous system | |
| IL277805A (en) | Use of gaboksadol in the treatment of substance use disorders | |
| IL269894B (en) | Small organic molecules for use in the treatment of neuroinflammatory diseases | |
| IL284032A (en) | 3 beta-(benzyloxy)-17 alpha-methyl-paragan-5-en-20-one for use in the treatment of cognitive disorders | |
| IL276697A (en) | 3 Beta-(4-methoxybenzyloxy)paragan-5-en-20-one for use in the treatment of cannabinoid-related disorders | |
| LT3906927T (lt) | Dalinių dopamino d3 agonistų naudojimas centrinės nervų sistemos sutrikimams gydyti | |
| ZA201806894B (en) | (+)-azasetron for use in the treatment of ear disorders | |
| PT3442537T (pt) | (+)-azasetrom para utilização no tratamento de doenças do ouvido |